FindTrial
Sign In

Serum neutrophil gelatinase associated lipocalin (NGAL) as early predictor of contrast-induced acute kidney injury after cerebral angiography

Serum neutrophil gelatinase associated lipocalin (NGAL) as early predictor of contrast-induced acute kidney injury after cerebral angiography

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0004003
Enrollment
390
Registered
2019-05-28
Start date
2019-03-18
Completion date
Unknown
Last updated
2019-06-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Seoul National University Bundang Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients who have been determined to perform cerebral angiography 2. The person who finally agreed to the research

Exclusion criteria

Exclusion criteria: 1. Patients undergoing treatment for existing renal disease 2. Patients with an initial GFR less than 60mL/min/1.73m^2 3. Patients with contrast agent allergy 4. Patients who do not agree to participate in the study 5. If a research person is deemed unfit by the researcher

Design outcomes

Primary

MeasureTime frame
Difference of post-4hr Neutrophil gelatinase-associated lipocalin levels between acute kidney injury and control patients—

Secondary

MeasureTime frame
Cut-off value of NGAL for predicting AKI—

Countries

Korea, Republic of

Contacts

Public ContactTackeun Kim

Seoul National University Bundang Hospital

midabo@naver.com+82-31-787-7161

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026